BioLingus Breakthrough to Trade Injections for Sublingual Delivery - European CEO - Video

Injections aren't anybody's favourite healthcare intervention. BioLingus, a Swiss biotechnology firm, has developed a technology that can stabilise different molecules for sublingual delivery – a simple tablet that goes under the tongue. CEO Yves Decadt explains the technology BioLingus has developed, which enables biological molecules – which typically have to be injected, because the body is designed to degrade them – to be delivered sublingually in a pill. The stabilisation technology is inspired by nature, he explains, where plant seeds can preserve proteins and peptides for centuries. And stable molecules don't just mean no more needles – they mean more cost-effective treatments with potentially lower side-effects.